ABBOTT LABORATORIES·4

Feb 22, 7:20 PM ET

Tyler Julie L. 4

4 · ABBOTT LABORATORIES · Filed Feb 22, 2023

Insider Transaction Report

Form 4
Period: 2023-02-17
Tyler Julie L.
SENIOR VICE PRESIDENT
Transactions
  • Tax Payment

    Common shares without par value

    2023-02-21$106.74/sh341$36,39841,156 total
  • Tax Payment

    Common shares without par value

    2023-02-19$106.74/sh291$31,06141,497 total
  • Sale

    Common shares without par value

    2023-02-22$103.24/sh260$26,84240,896 total
  • Award

    Common shares without par value

    2023-02-17+7,92041,788 total
  • Award

    Option (right to buy)

    2023-02-17+31,23631,236 total
    Exercise: $106.24From: 2024-02-17Exp: 2033-02-16Common Shares (31,236 underlying)
Holdings
  • Common shares without par value

    (indirect: By Trust)
    9,513
Footnotes (3)
  • [F1]These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
  • [F2]Balance in the Abbott Laboratories Stock Retirement Trust as of February 17, 2023.
  • [F3]Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,412 on February 17, 2024, 10,412 on February 17, 2025 and 10,412 on February 17, 2026.

Documents

1 file
  • 4
    form4-02232023_120213.xmlPrimary